Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a report published on Sunday morning.

Several other research firms have also commented on REGN. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. UBS Group increased their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Finally, Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $796.57.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $2.79 during trading hours on Friday, reaching $654.74. 824,792 shares of the stock were exchanged, compared to its average volume of 1,094,189. The stock has a market capitalization of $69.39 billion, a P/E ratio of 15.68, a P/E/G ratio of 2.03 and a beta of 0.31. The firm has a 50 day simple moving average of $588.03 and a 200-day simple moving average of $567.90. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $834.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company posted $12.46 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in REGN. PGGM Investments boosted its position in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after acquiring an additional 51,900 shares during the period. Founders Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares during the last quarter. Sepio Capital LP boosted its holdings in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares during the period. Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $6,300,000. Finally, Bellecapital International Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after purchasing an additional 6,283 shares during the period. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.